A5025630398- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Lung Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Medical Imaging and Pathology Studies
- Colorectal Cancer Treatments and Studies
- Medical Imaging Techniques and Applications
- Pleural and Pulmonary Diseases
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Cancer-related Molecular Pathways
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
Kliniken Essen-Mitte
2018-2024
Essen University Hospital
2009-2021
West German Heart and Vascular Center Essen
2009-2021
University of Münster
2021
University of Duisburg-Essen
2012-2020
West Cancer Center
2011-2019
Ruhrlandklinik
2012-2017
Fondazione IRCCS Istituto Nazionale dei Tumori
2017
Sarah Cannon
2017
Dana-Farber Cancer Institute
2017
Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cancer (NSCLC) across lines therapy. Patients were selected on basis PD-L1 expression tumor cells (TC) or tumor-infiltrating immune (IC). and Methods Eligible patients had advanced-stage NSCLC, no CNS metastases, zero two more prior chemotherapy. whose tumors expressed using SP142 immunohistochemistry assay ≥ 5% TC IC...
The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). observational PACIFIC-R study assesses the real-world effectiveness in from an early access program. Here, we report treatment characteristics a preplanned analysis progression-free survival (rwPFS).PACIFIC-R (NCT03798535) is ongoing, international, retrospective who started...
PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab TKI-resistant, nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults...
PURPOSE Although checkpoint inhibitors have improved first-line treatment for non–small cell lung cancer (NSCLC), a therapeutic need remains patients whose disease does not respond or who experience progression after anti–PD-L1/PD-1 immunotherapy. CONTACT-01 (ClinicalTrials.gov identifier: NCT04471428 ) evaluated atezolizumab plus cabozantinib versus docetaxel in with metastatic NSCLC developed concurrent sequential and platinum-containing chemotherapy. METHODS This multicenter, open-label,...
•The PACIFIC trial established durvalumab after CRT as a global standard of care for unresectable stage III NSCLC.•PACIFIC-R is an observational study cohort patients who received through early access program.•PACIFIC-R data are broadly consistent with outcomes from and real-world studies the regimen.•Encouraging were observed across subgroups, including among sCRT PD-L1 TCs <1%.•These support continued use regimen NSCLC. BackgroundBased on findings trial, consolidation following...
Lung cancer is the leading cause of cancer-related deaths worldwide. The typical and atypical carcinoid (TC AC), large-cell neuroendocrine carcinoma (LCNEC) small-cell lung cancers (SCLC) are subgroups pulmonary tumours that show differentiations. With rising impact molecular pathology in routine diagnostics interest for reliable biomarkers, which can help to differentiate these may enable a more personalised treatment patients, grows. A collective 70 formalin-fixed, paraffin-embedded (FFPE)...
We report on the results of German early access program (EAP) with third-generation ALK- and ROS1-inhibitor lorlatinib.Patients documented treatment failure all approved ALK/ROS1-specific therapies or resistance mutations not covered by inhibitors leptomeningeal carcinomatosis were enrolled analyzed.In total, 52 patients included [median age 57 years (range 32-81), 54% female, 62% never smokers, 98% adenocarcinoma]; 71% 29% ROS1-positive, respectively. G1202R G2032R prior to lorlatinib...
Safety margins in pulmonary metastasectomy are not yet well defined. We hypothesize that histological subtype, size of the lesion and local growth characteristics must be taken into consideration during metastasectomy. This study was conducted to examine classify patterns at resection define relationships between aggressive growth, metastasis recurrence direct metastasectomy.Histologic sections metastases were prospectively collected haematoxylin-eosin stains systematically evaluated...
Background Neuroendocrine lung cancer (NELC) represents 25% of all cases and large patient collectives exist as formalin-fixed, paraffin-embedded (FFPE) tissue only. FFPE is controversially discussed source for molecular biological analyses reference genes NELC are poorly establishes. Material methods Forty-three representative FFPE-specimens were used mRNA expression analysis using the digital nCounter technology (NanoString). Based on recent literature, a total 91 targets investigated...
Anti-PD1 monoclonal antibody nivolumab is an approved therapy option for the treatment of advanced squamous cell non-small lung cancer (SQ-NSCLC) patients. Data outside clinical trials about efficacy and safety in later line treatments have rarely been described until now.We performed a retrospective data analysis patients who were enrolled into nivolu-mab Compassionate Use Program (CUP) Germany. Sufficient 40 available analysis.Overall, 47.5% all treated not affected by any adverse events...
Malignant pleural mesothelioma (MPM) is a tumour arising from cavities with poor prognosis. Multimodality treatment pemetrexed combined cisplatin shows unsatisfying response-rates of 40%. The reasons for the rather efficacy chemotherapeutic are largely unknown. However, it conceivable that DNA repair mechanisms lead to an impaired therapy response. We hypothesize major role homologous recombination (HR) genome stability and survival this tumour. Therefore, we analysed genes compiled under...
Tubulin-binding agents (TBAs) are effective in non-small cell lung cancer (NSCLC) treatment. Both βIII- and βV-tubulins expressed by cells may lead to resistance against TBAs. Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel platinum followed radiochemotherapy vinorelbine were retrospectively analysed immunohistochemistry. Protein expression of βV-tubulin was morphometrically quantified. Median...
Background: Neuroendocrine tumors of the lung (NELC) account for 25% all cancer cases and transcription factors may drive dedifferentiation these tumors. This study was conducted to identify supportive diagnostic prognostic biomarkers. Materials & methods: A total 16 TC, 13 AC, large cell neuroendocrine carcinomas 15 small were investigated mRNA expression 11 related genes (MYB, MYBBP1A, OCT4, PAX6, PCDHB, RBP1, SDCBP, SOX2, SOX4, SOX11, TEAD2). Results: SOX4 (p = 0.0002), SOX11 < 0.0001)...
Proteasomal subunit PSMB4 was suggested to be a survival gene in an animal model of hepatocellular carcinoma and glioblastoma cell lines. In pulmonary adenocarcinoma, high expression these genes found associated with poor differentiation survival. This study investigates the levels 26S proteasome subunits human neuroendocrine tumours including typical (TC) atypical (AC) carcinoid as well small (SCLC) large (LCNEC) carcinomas.Gene proteasomal (PSMA1, PSMA5, PSMB4, PSMB5 PSMD1) were...
Introduction Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa-inhibitors as rivaroxaban for > 3 months. Patient’s preference convenience an important factor to guide decision support adherence. No data are available so far about patient-reported outcome in CAT. Methods CONKO-011 was open-label, prospective, multicenter German phase III trial cancer...